The DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
Bisphosphonates: mechanisms of action.
Open accessAbstract
Because of its failure to act when given orally and its rapid hydrolysis when given parenterally, pyrophosphate was used therapeutically only in scintigraphy and against dental calculus. This prompted us to search for analogs that showed similar physicochemical activity but resisted enzymatic hydrolysis and, therefore, would not be degraded metabolically. The bisphosphonates fulfilled these conditions. This review will deal with the mechanisms of action of these compounds. In vitro results, as well as results both in animals and humans, will be integrated in an attempt to deduce the current state of the art. Various reviews have been published recently on bisphosphonates and may be consulted also for information on other aspects (8 ‐14). Since the literature in this field is plentiful, selective citation was necessary. Priority is given to papers dealing with the mechanisms of action. Since many papers often deal with the same finding, in most cases only the first ones are quoted. Subsequent papers are quoted only if they convey new knowledge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wimalawansa, S. J. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80102-8 · Cited by 152
RetractedCaspases: the executioners of apoptosis
COHEN, G. M. (1997) · Biochemical Journal · doi:10.1042/bj3260001 · Cited by 4,719
Ridley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling
Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90164-8 · Cited by 3,652
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 1,743
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Cited by
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Self-citationThe Epidemiology of Distal Radius Fractures
Nellans, K. W., Kowalski, E., & Chung, K. C. (2012) · Hand Clinics · doi:10.1016/j.hcl.2012.02.001 · Cited by 898
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890
Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
Hidalgo, M., & Eckhardt, S. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.178 · Cited by 798
The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway
Delanian, S., & Lefaix, J.-L. (2004) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2004.08.021 · Cited by 723
Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Self-citationKunzmann, V., Bauer, E., Feurle, J., Tony, F. W., & Wilhelm, M. (2000) · Blood · doi:10.1182/blood.v96.2.384 · Cited by 669
Hoff, A. O., Toth, B. B., Altundag, K., Johnson, M. M., Warneke, C. L., Hu, M., Nooka, A., Sayegh, G., Guarneri, V., Desrouleaux, K., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080205 · Cited by 633
Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION
Goh, S.-K., Yang, K. Y., Koh, J. S. B., Wong, M. K., Chua, S. Y., Chua, D. T. C., & Howe, T. S. (2007) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.89b3.18146 · Cited by 513
Ruggiero, S. L., Fantasia, J., & Carlson, E. (2006) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2006.06.004 · Cited by 507
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Allen, M. R., & Burr, D. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.007 · Cited by 451
Bisphosphonate-Induced Osteopetrosis
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023110 · Cited by 446
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Regulation of Osteoclast Function
Suda, T., Nakamura, I., Jimi, E., & Takahashi, N. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.869 · Cited by 408
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., & Rodan, G. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1502 · Cited by 402
Self-citationBisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity
Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2713086.x · Cited by 398
Osteoblast proliferation and maturation by bisphosphonates
Im, G.-I., Qureshi, S. A., Kenney, J., Rubash, H. E., & Shanbhag, A. S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.11.024 · Cited by 393
Riggs, B. L., & Parfitt, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 380
Hansen, T., Kunkel, M., Weber, A., & James Kirkpatrick, C. (2006) · Journal of Oral Pathology & Medicine · doi:10.1111/j.1600-0714.2006.00391.x · Cited by 368
Lai, K.-A. (2005) · The Journal of Bone and Joint Surgery (American) · doi:10.2106/jbjs.d.02959 · Cited by 332
Tumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324
Osteoradionecrosis of the jaws: current understanding of its pathophysiology and treatment
Lyons, A., & Ghazali, N. (2008) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2008.04.006 · Cited by 322
Pharmacokinetics of Alendronate
Porras, A. G., Holland, S. D., & Gertz, B. J. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936050-00002 · Cited by 296
Current Management for Late Normal Tissue Injury: Radiation-Induced Fibrosis and Necrosis
Delanian, S., & Lefaix, J.-L. (2007) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2006.11.006 · Cited by 292
Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
Wesolowski, R., Markowitz, J., & Carson, W. E. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-10 · Cited by 291
Prevention and treatment of systemic glucocorticoid side effects
Moghadam‐Kia, S., & Werth, V. P. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2009.04322.x · Cited by 286
Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
Draghiciu, O., Lubbers, J., Nijman, H. W., & Daemen, T. (2015) · OncoImmunology · doi:10.4161/21624011.2014.954829 · Cited by 274
Gómez-Morales, J., Iafisco, M., Delgado-López, J. M., Sarda, S., & Drouet, C. (2013) · Progress in Crystal Growth and Characterization of Materials · doi:10.1016/j.pcrysgrow.2012.11.001 · Cited by 271
Giuliani, N., Pedrazzoni, M., Negri, G., Passeri, G., Impicciatore, M., & Girasole, G. (1998) · Bone · doi:10.1016/s8756-3282(98)00033-7 · Cited by 269
Delanian, S., Depondt, J., & Lefaix, J.-L. (2005) · Head & Neck · doi:10.1002/hed.20121 · Cited by 264
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Allen, M. R., Iwata, K., Phipps, R., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.04.028 · Cited by 253
Cao, Y., Mori, S., Mashiba, T., Westmore, M. S., Ma, L., Sato, M., Akiyama, T., Shi, L., Komatsubara, S., Miyamoto, K., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.12.2237 · Cited by 248
Allen, M. R., & Burr, D. B. (2011) · Bone · doi:10.1016/j.bone.2010.10.159 · Cited by 219
Lloyd, A. A., Gludovatz, B., Riedel, C., Luengo, E. A., Saiyed, R., Marty, E., Lorich, D. G., Lane, J. M., Ritchie, R. O., Busse, B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704460114 · Cited by 158
(2005) · PubMed · Cited by 135
Inoue, Y., Shimojo, N., Suzuki, S., Arima, T., Tomiita, M., Minagawa, M., & Kohno, Y. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0864-6 · Cited by 34
Jörg, D. J., Fuertinger, D. H., Cherif, A., Bushinsky, D. A., Mermelstein, A., Raimann, J. G., & Kotanko, P. (2022) · eLife · doi:10.7554/elife.76228 · Cited by 15
Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women
Um, M. J., Cho, E. A., & Jung, H. (2017) · Journal of Menopausal Medicine · doi:10.6118/jmm.2017.23.1.56 · Cited by 14
Metadata
- Authors
- Rodan, G. A., & Fleisch, H. A.
- Venue
- Journal of Clinical Investigation
- Published
- 1996-06-15
- Volume
- 97
- Issue
- 12
- Pages
- 2692-2696
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1993232754
- Cited by
- 921
- References
- 246
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.